[144] BioXcel Therapeutics, Inc. SEC Filing
Rhea-AI Filing Summary
BioXcel Therapeutics filed a Form 144 reporting the vesting and proposed sale of 6,845 shares of Common Stock. The securities are described as restricted stock unit awards that vested on 05/04/2026. The filing shows 30,877,605 shares outstanding as of 05/20/2026 on NASDAQ.
Positive
- None.
Negative
- None.
Insights
Form 144 reports a routine post-vesting resale notice for RSUs.
Form 144 is a notice required under applicable rules when control/affiliate holders intend to sell restricted or control securities. The filing lists 6,845 shares from restricted stock units that vested on 05/04/2026.
Timing and specific sale mechanics are not detailed; subsequent transaction results will appear in transfer or broker records or in a Form 4/5 if required. Cash‑flow treatment is not stated in the excerpt.